Management of Acute Ischaemic Stroke
Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a fa...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Johnsen, Søren Paaske [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1999 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Adis International Limited 1999 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Disease Management & Health Outcomes - Springer International Publishing, 1997, 5(1999), 6 vom: Juni, Seite 311-327 |
|---|---|
| Übergeordnetes Werk: |
volume:5 ; year:1999 ; number:6 ; month:06 ; pages:311-327 |
| Links: |
|---|
| DOI / URN: |
10.2165/00115677-199905060-00002 |
|---|
| Katalog-ID: |
SPR035651199 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR035651199 | ||
| 003 | DE-627 | ||
| 005 | 20230519112300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1999 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00115677-199905060-00002 |2 doi | |
| 035 | |a (DE-627)SPR035651199 | ||
| 035 | |a (SPR)00115677-199905060-00002-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Johnsen, Søren Paaske |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of Acute Ischaemic Stroke |
| 264 | 1 | |c 1999 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Adis International Limited 1999 | ||
| 520 | |a Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy. | ||
| 650 | 4 | |a Adis International Limited |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acute Stroke |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acute Ischaemic Stroke |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Alteplase |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Stroke Unit |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Husted, Steen Elkjær |4 aut | |
| 700 | 1 | |a Thomassen, Anne |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Disease Management & Health Outcomes |d Springer International Publishing, 1997 |g 5(1999), 6 vom: Juni, Seite 311-327 |w (DE-627)SPR035648813 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:1999 |g number:6 |g month:06 |g pages:311-327 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00115677-199905060-00002 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 1999 |e 6 |c 06 |h 311-327 | ||
| author_variant |
s p j sp spj s e h se seh a t at |
|---|---|
| matchkey_str |
johnsensrenpaaskehustedsteenelkjrthomass:1999----:aaeetfcticam |
| hierarchy_sort_str |
1999 |
| publishDate |
1999 |
| allfields |
10.2165/00115677-199905060-00002 doi (DE-627)SPR035651199 (SPR)00115677-199905060-00002-e DE-627 ger DE-627 rakwb eng Johnsen, Søren Paaske verfasserin aut Management of Acute Ischaemic Stroke 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 1999 Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy. Adis International Limited (dpeaa)DE-He213 Acute Stroke (dpeaa)DE-He213 Acute Ischaemic Stroke (dpeaa)DE-He213 Alteplase (dpeaa)DE-He213 Stroke Unit (dpeaa)DE-He213 Husted, Steen Elkjær aut Thomassen, Anne aut Enthalten in Disease Management & Health Outcomes Springer International Publishing, 1997 5(1999), 6 vom: Juni, Seite 311-327 (DE-627)SPR035648813 nnns volume:5 year:1999 number:6 month:06 pages:311-327 https://dx.doi.org/10.2165/00115677-199905060-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 5 1999 6 06 311-327 |
| spelling |
10.2165/00115677-199905060-00002 doi (DE-627)SPR035651199 (SPR)00115677-199905060-00002-e DE-627 ger DE-627 rakwb eng Johnsen, Søren Paaske verfasserin aut Management of Acute Ischaemic Stroke 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 1999 Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy. Adis International Limited (dpeaa)DE-He213 Acute Stroke (dpeaa)DE-He213 Acute Ischaemic Stroke (dpeaa)DE-He213 Alteplase (dpeaa)DE-He213 Stroke Unit (dpeaa)DE-He213 Husted, Steen Elkjær aut Thomassen, Anne aut Enthalten in Disease Management & Health Outcomes Springer International Publishing, 1997 5(1999), 6 vom: Juni, Seite 311-327 (DE-627)SPR035648813 nnns volume:5 year:1999 number:6 month:06 pages:311-327 https://dx.doi.org/10.2165/00115677-199905060-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 5 1999 6 06 311-327 |
| allfields_unstemmed |
10.2165/00115677-199905060-00002 doi (DE-627)SPR035651199 (SPR)00115677-199905060-00002-e DE-627 ger DE-627 rakwb eng Johnsen, Søren Paaske verfasserin aut Management of Acute Ischaemic Stroke 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 1999 Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy. Adis International Limited (dpeaa)DE-He213 Acute Stroke (dpeaa)DE-He213 Acute Ischaemic Stroke (dpeaa)DE-He213 Alteplase (dpeaa)DE-He213 Stroke Unit (dpeaa)DE-He213 Husted, Steen Elkjær aut Thomassen, Anne aut Enthalten in Disease Management & Health Outcomes Springer International Publishing, 1997 5(1999), 6 vom: Juni, Seite 311-327 (DE-627)SPR035648813 nnns volume:5 year:1999 number:6 month:06 pages:311-327 https://dx.doi.org/10.2165/00115677-199905060-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 5 1999 6 06 311-327 |
| allfieldsGer |
10.2165/00115677-199905060-00002 doi (DE-627)SPR035651199 (SPR)00115677-199905060-00002-e DE-627 ger DE-627 rakwb eng Johnsen, Søren Paaske verfasserin aut Management of Acute Ischaemic Stroke 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 1999 Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy. Adis International Limited (dpeaa)DE-He213 Acute Stroke (dpeaa)DE-He213 Acute Ischaemic Stroke (dpeaa)DE-He213 Alteplase (dpeaa)DE-He213 Stroke Unit (dpeaa)DE-He213 Husted, Steen Elkjær aut Thomassen, Anne aut Enthalten in Disease Management & Health Outcomes Springer International Publishing, 1997 5(1999), 6 vom: Juni, Seite 311-327 (DE-627)SPR035648813 nnns volume:5 year:1999 number:6 month:06 pages:311-327 https://dx.doi.org/10.2165/00115677-199905060-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 5 1999 6 06 311-327 |
| allfieldsSound |
10.2165/00115677-199905060-00002 doi (DE-627)SPR035651199 (SPR)00115677-199905060-00002-e DE-627 ger DE-627 rakwb eng Johnsen, Søren Paaske verfasserin aut Management of Acute Ischaemic Stroke 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 1999 Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy. Adis International Limited (dpeaa)DE-He213 Acute Stroke (dpeaa)DE-He213 Acute Ischaemic Stroke (dpeaa)DE-He213 Alteplase (dpeaa)DE-He213 Stroke Unit (dpeaa)DE-He213 Husted, Steen Elkjær aut Thomassen, Anne aut Enthalten in Disease Management & Health Outcomes Springer International Publishing, 1997 5(1999), 6 vom: Juni, Seite 311-327 (DE-627)SPR035648813 nnns volume:5 year:1999 number:6 month:06 pages:311-327 https://dx.doi.org/10.2165/00115677-199905060-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 5 1999 6 06 311-327 |
| language |
English |
| source |
Enthalten in Disease Management & Health Outcomes 5(1999), 6 vom: Juni, Seite 311-327 volume:5 year:1999 number:6 month:06 pages:311-327 |
| sourceStr |
Enthalten in Disease Management & Health Outcomes 5(1999), 6 vom: Juni, Seite 311-327 volume:5 year:1999 number:6 month:06 pages:311-327 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Adis International Limited Acute Stroke Acute Ischaemic Stroke Alteplase Stroke Unit |
| isfreeaccess_bool |
false |
| container_title |
Disease Management & Health Outcomes |
| authorswithroles_txt_mv |
Johnsen, Søren Paaske @@aut@@ Husted, Steen Elkjær @@aut@@ Thomassen, Anne @@aut@@ |
| publishDateDaySort_date |
1999-06-01T00:00:00Z |
| hierarchy_top_id |
SPR035648813 |
| id |
SPR035651199 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035651199</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519112300.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1999 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00115677-199905060-00002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035651199</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00115677-199905060-00002-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Johnsen, Søren Paaske</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Management of Acute Ischaemic Stroke</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Limited 1999</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Stroke</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Ischaemic Stroke</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alteplase</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Stroke Unit</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Husted, Steen Elkjær</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thomassen, Anne</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Disease Management & Health Outcomes</subfield><subfield code="d">Springer International Publishing, 1997</subfield><subfield code="g">5(1999), 6 vom: Juni, Seite 311-327</subfield><subfield code="w">(DE-627)SPR035648813</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:6</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:311-327</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00115677-199905060-00002</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">1999</subfield><subfield code="e">6</subfield><subfield code="c">06</subfield><subfield code="h">311-327</subfield></datafield></record></collection>
|
| author |
Johnsen, Søren Paaske |
| spellingShingle |
Johnsen, Søren Paaske misc Adis International Limited misc Acute Stroke misc Acute Ischaemic Stroke misc Alteplase misc Stroke Unit Management of Acute Ischaemic Stroke |
| authorStr |
Johnsen, Søren Paaske |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR035648813 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Management of Acute Ischaemic Stroke Adis International Limited (dpeaa)DE-He213 Acute Stroke (dpeaa)DE-He213 Acute Ischaemic Stroke (dpeaa)DE-He213 Alteplase (dpeaa)DE-He213 Stroke Unit (dpeaa)DE-He213 |
| topic |
misc Adis International Limited misc Acute Stroke misc Acute Ischaemic Stroke misc Alteplase misc Stroke Unit |
| topic_unstemmed |
misc Adis International Limited misc Acute Stroke misc Acute Ischaemic Stroke misc Alteplase misc Stroke Unit |
| topic_browse |
misc Adis International Limited misc Acute Stroke misc Acute Ischaemic Stroke misc Alteplase misc Stroke Unit |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Disease Management & Health Outcomes |
| hierarchy_parent_id |
SPR035648813 |
| hierarchy_top_title |
Disease Management & Health Outcomes |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR035648813 |
| title |
Management of Acute Ischaemic Stroke |
| ctrlnum |
(DE-627)SPR035651199 (SPR)00115677-199905060-00002-e |
| title_full |
Management of Acute Ischaemic Stroke |
| author_sort |
Johnsen, Søren Paaske |
| journal |
Disease Management & Health Outcomes |
| journalStr |
Disease Management & Health Outcomes |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1999 |
| contenttype_str_mv |
txt |
| container_start_page |
311 |
| author_browse |
Johnsen, Søren Paaske Husted, Steen Elkjær Thomassen, Anne |
| container_volume |
5 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Johnsen, Søren Paaske |
| doi_str_mv |
10.2165/00115677-199905060-00002 |
| title_sort |
management of acute ischaemic stroke |
| title_auth |
Management of Acute Ischaemic Stroke |
| abstract |
Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy. © Adis International Limited 1999 |
| abstractGer |
Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy. © Adis International Limited 1999 |
| abstract_unstemmed |
Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy. © Adis International Limited 1999 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
6 |
| title_short |
Management of Acute Ischaemic Stroke |
| url |
https://dx.doi.org/10.2165/00115677-199905060-00002 |
| remote_bool |
true |
| author2 |
Husted, Steen Elkjær Thomassen, Anne |
| author2Str |
Husted, Steen Elkjær Thomassen, Anne |
| ppnlink |
SPR035648813 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2165/00115677-199905060-00002 |
| up_date |
2024-07-03T15:31:11.885Z |
| _version_ |
1803572396048777216 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035651199</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519112300.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1999 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00115677-199905060-00002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035651199</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00115677-199905060-00002-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Johnsen, Søren Paaske</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Management of Acute Ischaemic Stroke</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Limited 1999</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Stroke is a leading cause of death and disability and continues to have a great public health impact worldwide. Management of patients with acute ischaemic stroke (IS) has been, until recently, primarily supportive care. A better understanding of the mechanisms of stroke has stimulated a far more aggressive and active treatment strategy, and stroke is now considered a state of medical emergency. Evidence-based protocols for the management of patients with stroke should be implemented in all hospital departments involved in the diagnosis and treatment of such individuals. These protocols should include assessment, investigation, immediate treatment and rehabilitation, as well as secondary prevention and risk factor management strategies. Specialised stroke units are well documented initiatives for optimising the management of patients with stroke and are central to the future of acute stroke management. Establishment of stroke units should receive top priority in strategic planning within the area of stroke management. Immediate and precise evaluation of patients with assumed stroke, including a computerised tomography scan of the brain followed by close monitoring, are essential for preventing medical and neurological complications and for achieving the optimal outcome. Primary treatment of acute IS with thrombolysis is a therapy with substantial risks, but at present is essentially the only available therapy for reversing or reducing effects of acute IS. Antiplatelet therapy with aspirin (acetylsalicylic acid) in the acute phase of IS also has a small but significant effect. Anticoagulant therapy with heparin has not yet proven any net long term benefit in the treatment of acute IS. Likewise, there are currently no convincing data on the efficacy of neuroprotective drugs in a clinical setting. Every patient should have disability needs assessed as soon as possible and a well conceived rehabilitation plan should be made based on the patients’s own goals. To reduce the incidence of a subsequent stroke, secondary prevention is essential. Prevention should primarily focus on detection and management of risk factors for stroke, which in many cases influence both the risk of ischaemic and haemorrhagic stroke. These risk factors include hypertension, atrial fibrillation, smoking, diabetes mellitus, alcohol abuse and hyperlipidaemia. In patients with IS, secondary prevention also includes antiplatelet therapy with aspirin and dipyridamole or clopidogrel and the possibility of carotid endarterectomy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Stroke</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Ischaemic Stroke</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alteplase</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Stroke Unit</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Husted, Steen Elkjær</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thomassen, Anne</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Disease Management & Health Outcomes</subfield><subfield code="d">Springer International Publishing, 1997</subfield><subfield code="g">5(1999), 6 vom: Juni, Seite 311-327</subfield><subfield code="w">(DE-627)SPR035648813</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:6</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:311-327</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00115677-199905060-00002</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">1999</subfield><subfield code="e">6</subfield><subfield code="c">06</subfield><subfield code="h">311-327</subfield></datafield></record></collection>
|
| score |
7.3989944 |